Global Generic Injectables

Generic Injectables Comprehensive Study by Type (Large Molecule Injectable {Monoclonal Antibodies (Mab), Insulin, And Others}, Small Molecule Injectable), Application (Oncology, Infectious Diseases, Cardiology, Diabetes, Immunology), Route of Administration (Intravenous, Intramuscular, Subcutaneous, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Stores Online, Prescription Stores, Others), Container Type (Vials, Ampoules, Premixes, Prefilled Syringes, Others) Players and Region - Global Market Outlook to 2030

Generic Injectables Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 12%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Generic Injectables
The generic injectable is defined as the pharmaceutical drugs that are available in large molecule injectable and small molecule injectable. Rising prevalence of chronic, increasing disposal income among middle-class families, increasing awareness regarding the benefit of generic injectable are some of the major factors which affect the growth of the market in the future.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR12.0%


The global injectable market is highly fragmented with the presence of various players operating in the market. Some of the major players operating in the market are Pfizer Inc. (United States), Sandoz International (Germany), Sagent Pharmaceuticals (United States), among others. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Generic Injectables market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer Inc. (United States), Sandoz International (Germany), Sagent Pharmaceuticals (United States), Baxter International Inc. (United States), Fresenius Medical Care AG & Co. KGaA (Germany), Mylan N.V. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Hikma Pharmaceuticals (United Kingdom), Lupin Pharmaceuticals (India) and Sanofi S.A. (France) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Biocon Limited (India).

Segmentation Overview
AMA Research has segmented the market of Global Generic Injectables market by Type (Large Molecule Injectable {Monoclonal Antibodies (Mab), Insulin, And Others} and Small Molecule Injectable), Application (Oncology, Infectious Diseases, Cardiology, Diabetes and Immunology) and Region.



On the basis of geography, the market of Generic Injectables has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Intravenous will boost the Generic Injectables market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Generic Injectables market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Container Type, the sub-segment i.e. Vials will boost the Generic Injectables market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technology Advancement regrading Generic Injectable

Market Growth Drivers:
Due to rise in incidence of cancer in Asia Pacific countries such as India and China are expected to witness fastest market growth during the forecast period. For instance, According to an article published by World Health Organization, in 2018, Cancer is the second leading cause of death across the world and accounting for an expected more than 9.6 million deaths. Hence, rising number of cancer will affect the growth of market in future.

Challenges:
Issue related to High Barriers to Entry Led by Complex Manufacturing Process

Restraints:
Stringent Rules as well as Regulation

Opportunities:
Growing Demand from Emerging Market such as China, India, and others

Market Leaders and their expansionary development strategies




Key Target Audience
Manufacturers of Generic Injectables, Research and Development (R&D) Companies, Research Organization, Federal Agencies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Large Molecule Injectable {Monoclonal Antibodies (Mab), Insulin, And Others}
  • Small Molecule Injectable
By Application
  • Oncology
  • Infectious Diseases
  • Cardiology
  • Diabetes
  • Immunology
By Route of Administration
  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Others

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Drug Stores Online
  • Prescription Stores
  • Others

By Container Type
  • Vials
  • Ampoules
  • Premixes
  • Prefilled Syringes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Due to rise in incidence of cancer in Asia Pacific countries such as India and China are expected to witness fastest market growth during the forecast period. For instance, According to an article published by World Health Organization, in 2018, Cancer is the second leading cause of death across the world and accounting for an expected more than 9.6 million deaths. Hence, rising number of cancer will affect the growth of market in future.
    • 3.3. Market Challenges
      • 3.3.1. Issue related to High Barriers to Entry Led by Complex Manufacturing Process
    • 3.4. Market Trends
      • 3.4.1. Technology Advancement regrading Generic Injectable
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Generic Injectables, by Type, Application, Route of Administration, Distribution Channel, Container Type and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Generic Injectables (Value)
      • 5.2.1. Global Generic Injectables by: Type (Value)
        • 5.2.1.1. Large Molecule Injectable {Monoclonal Antibodies (Mab), Insulin, And Others}
        • 5.2.1.2. Small Molecule Injectable
      • 5.2.2. Global Generic Injectables by: Application (Value)
        • 5.2.2.1. Oncology
        • 5.2.2.2. Infectious Diseases
        • 5.2.2.3. Cardiology
        • 5.2.2.4. Diabetes
        • 5.2.2.5. Immunology
      • 5.2.3. Global Generic Injectables by: Route of Administration (Value)
        • 5.2.3.1. Intravenous
        • 5.2.3.2. Intramuscular
        • 5.2.3.3. Subcutaneous
        • 5.2.3.4. Others
      • 5.2.4. Global Generic Injectables by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacy
        • 5.2.4.2. Retail Pharmacy
        • 5.2.4.3. Drug Stores Online
        • 5.2.4.4. Prescription Stores
        • 5.2.4.5. Others
      • 5.2.5. Global Generic Injectables by: Container Type (Value)
        • 5.2.5.1. Vials
        • 5.2.5.2. Ampoules
        • 5.2.5.3. Premixes
        • 5.2.5.4. Prefilled Syringes
        • 5.2.5.5. Others
      • 5.2.6. Global Generic Injectables Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Generic Injectables (Volume)
      • 5.3.1. Global Generic Injectables by: Type (Volume)
        • 5.3.1.1. Large Molecule Injectable {Monoclonal Antibodies (Mab), Insulin, And Others}
        • 5.3.1.2. Small Molecule Injectable
      • 5.3.2. Global Generic Injectables by: Application (Volume)
        • 5.3.2.1. Oncology
        • 5.3.2.2. Infectious Diseases
        • 5.3.2.3. Cardiology
        • 5.3.2.4. Diabetes
        • 5.3.2.5. Immunology
      • 5.3.3. Global Generic Injectables by: Route of Administration (Volume)
        • 5.3.3.1. Intravenous
        • 5.3.3.2. Intramuscular
        • 5.3.3.3. Subcutaneous
        • 5.3.3.4. Others
      • 5.3.4. Global Generic Injectables by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital Pharmacy
        • 5.3.4.2. Retail Pharmacy
        • 5.3.4.3. Drug Stores Online
        • 5.3.4.4. Prescription Stores
        • 5.3.4.5. Others
      • 5.3.5. Global Generic Injectables by: Container Type (Volume)
        • 5.3.5.1. Vials
        • 5.3.5.2. Ampoules
        • 5.3.5.3. Premixes
        • 5.3.5.4. Prefilled Syringes
        • 5.3.5.5. Others
      • 5.3.6. Global Generic Injectables Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Generic Injectables (Price)
      • 5.4.1. Global Generic Injectables by: Type (Price)
  • 6. Generic Injectables: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sandoz International (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sagent Pharmaceuticals (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Baxter International Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Fresenius Medical Care AG & Co. KGaA (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mylan N.V. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hikma Pharmaceuticals (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lupin Pharmaceuticals (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi S.A. (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Generic Injectables Sale, by Type, Application, Route of Administration, Distribution Channel, Container Type and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Generic Injectables (Value)
      • 7.2.1. Global Generic Injectables by: Type (Value)
        • 7.2.1.1. Large Molecule Injectable {Monoclonal Antibodies (Mab), Insulin, And Others}
        • 7.2.1.2. Small Molecule Injectable
      • 7.2.2. Global Generic Injectables by: Application (Value)
        • 7.2.2.1. Oncology
        • 7.2.2.2. Infectious Diseases
        • 7.2.2.3. Cardiology
        • 7.2.2.4. Diabetes
        • 7.2.2.5. Immunology
      • 7.2.3. Global Generic Injectables by: Route of Administration (Value)
        • 7.2.3.1. Intravenous
        • 7.2.3.2. Intramuscular
        • 7.2.3.3. Subcutaneous
        • 7.2.3.4. Others
      • 7.2.4. Global Generic Injectables by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacy
        • 7.2.4.2. Retail Pharmacy
        • 7.2.4.3. Drug Stores Online
        • 7.2.4.4. Prescription Stores
        • 7.2.4.5. Others
      • 7.2.5. Global Generic Injectables by: Container Type (Value)
        • 7.2.5.1. Vials
        • 7.2.5.2. Ampoules
        • 7.2.5.3. Premixes
        • 7.2.5.4. Prefilled Syringes
        • 7.2.5.5. Others
      • 7.2.6. Global Generic Injectables Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Generic Injectables (Volume)
      • 7.3.1. Global Generic Injectables by: Type (Volume)
        • 7.3.1.1. Large Molecule Injectable {Monoclonal Antibodies (Mab), Insulin, And Others}
        • 7.3.1.2. Small Molecule Injectable
      • 7.3.2. Global Generic Injectables by: Application (Volume)
        • 7.3.2.1. Oncology
        • 7.3.2.2. Infectious Diseases
        • 7.3.2.3. Cardiology
        • 7.3.2.4. Diabetes
        • 7.3.2.5. Immunology
      • 7.3.3. Global Generic Injectables by: Route of Administration (Volume)
        • 7.3.3.1. Intravenous
        • 7.3.3.2. Intramuscular
        • 7.3.3.3. Subcutaneous
        • 7.3.3.4. Others
      • 7.3.4. Global Generic Injectables by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital Pharmacy
        • 7.3.4.2. Retail Pharmacy
        • 7.3.4.3. Drug Stores Online
        • 7.3.4.4. Prescription Stores
        • 7.3.4.5. Others
      • 7.3.5. Global Generic Injectables by: Container Type (Volume)
        • 7.3.5.1. Vials
        • 7.3.5.2. Ampoules
        • 7.3.5.3. Premixes
        • 7.3.5.4. Prefilled Syringes
        • 7.3.5.5. Others
      • 7.3.6. Global Generic Injectables Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Generic Injectables (Price)
      • 7.4.1. Global Generic Injectables by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Generic Injectables: by Type(USD Million)
  • Table 2. Generic Injectables Large Molecule Injectable {Monoclonal Antibodies (Mab), Insulin, And Others} , by Region USD Million (2018-2023)
  • Table 3. Generic Injectables Small Molecule Injectable , by Region USD Million (2018-2023)
  • Table 4. Generic Injectables: by Application(USD Million)
  • Table 5. Generic Injectables Oncology , by Region USD Million (2018-2023)
  • Table 6. Generic Injectables Infectious Diseases , by Region USD Million (2018-2023)
  • Table 7. Generic Injectables Cardiology , by Region USD Million (2018-2023)
  • Table 8. Generic Injectables Diabetes , by Region USD Million (2018-2023)
  • Table 9. Generic Injectables Immunology , by Region USD Million (2018-2023)
  • Table 10. Generic Injectables: by Route of Administration(USD Million)
  • Table 11. Generic Injectables Intravenous , by Region USD Million (2018-2023)
  • Table 12. Generic Injectables Intramuscular , by Region USD Million (2018-2023)
  • Table 13. Generic Injectables Subcutaneous , by Region USD Million (2018-2023)
  • Table 14. Generic Injectables Others , by Region USD Million (2018-2023)
  • Table 15. Generic Injectables: by Distribution Channel(USD Million)
  • Table 16. Generic Injectables Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 17. Generic Injectables Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 18. Generic Injectables Drug Stores Online , by Region USD Million (2018-2023)
  • Table 19. Generic Injectables Prescription Stores , by Region USD Million (2018-2023)
  • Table 20. Generic Injectables Others , by Region USD Million (2018-2023)
  • Table 21. Generic Injectables: by Container Type(USD Million)
  • Table 22. Generic Injectables Vials , by Region USD Million (2018-2023)
  • Table 23. Generic Injectables Ampoules , by Region USD Million (2018-2023)
  • Table 24. Generic Injectables Premixes , by Region USD Million (2018-2023)
  • Table 25. Generic Injectables Prefilled Syringes , by Region USD Million (2018-2023)
  • Table 26. Generic Injectables Others , by Region USD Million (2018-2023)
  • Table 27. South America Generic Injectables, by Country USD Million (2018-2023)
  • Table 28. South America Generic Injectables, by Type USD Million (2018-2023)
  • Table 29. South America Generic Injectables, by Application USD Million (2018-2023)
  • Table 30. South America Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 31. South America Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 32. South America Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 33. Brazil Generic Injectables, by Type USD Million (2018-2023)
  • Table 34. Brazil Generic Injectables, by Application USD Million (2018-2023)
  • Table 35. Brazil Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 36. Brazil Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 37. Brazil Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 38. Argentina Generic Injectables, by Type USD Million (2018-2023)
  • Table 39. Argentina Generic Injectables, by Application USD Million (2018-2023)
  • Table 40. Argentina Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 41. Argentina Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 42. Argentina Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 43. Rest of South America Generic Injectables, by Type USD Million (2018-2023)
  • Table 44. Rest of South America Generic Injectables, by Application USD Million (2018-2023)
  • Table 45. Rest of South America Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 46. Rest of South America Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 47. Rest of South America Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 48. Asia Pacific Generic Injectables, by Country USD Million (2018-2023)
  • Table 49. Asia Pacific Generic Injectables, by Type USD Million (2018-2023)
  • Table 50. Asia Pacific Generic Injectables, by Application USD Million (2018-2023)
  • Table 51. Asia Pacific Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 52. Asia Pacific Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 53. Asia Pacific Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 54. China Generic Injectables, by Type USD Million (2018-2023)
  • Table 55. China Generic Injectables, by Application USD Million (2018-2023)
  • Table 56. China Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 57. China Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 58. China Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 59. Japan Generic Injectables, by Type USD Million (2018-2023)
  • Table 60. Japan Generic Injectables, by Application USD Million (2018-2023)
  • Table 61. Japan Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 62. Japan Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 63. Japan Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 64. India Generic Injectables, by Type USD Million (2018-2023)
  • Table 65. India Generic Injectables, by Application USD Million (2018-2023)
  • Table 66. India Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 67. India Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 68. India Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 69. South Korea Generic Injectables, by Type USD Million (2018-2023)
  • Table 70. South Korea Generic Injectables, by Application USD Million (2018-2023)
  • Table 71. South Korea Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 72. South Korea Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 73. South Korea Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 74. Taiwan Generic Injectables, by Type USD Million (2018-2023)
  • Table 75. Taiwan Generic Injectables, by Application USD Million (2018-2023)
  • Table 76. Taiwan Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 77. Taiwan Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 78. Taiwan Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 79. Australia Generic Injectables, by Type USD Million (2018-2023)
  • Table 80. Australia Generic Injectables, by Application USD Million (2018-2023)
  • Table 81. Australia Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 82. Australia Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 83. Australia Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 84. Rest of Asia-Pacific Generic Injectables, by Type USD Million (2018-2023)
  • Table 85. Rest of Asia-Pacific Generic Injectables, by Application USD Million (2018-2023)
  • Table 86. Rest of Asia-Pacific Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 87. Rest of Asia-Pacific Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 88. Rest of Asia-Pacific Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 89. Europe Generic Injectables, by Country USD Million (2018-2023)
  • Table 90. Europe Generic Injectables, by Type USD Million (2018-2023)
  • Table 91. Europe Generic Injectables, by Application USD Million (2018-2023)
  • Table 92. Europe Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 93. Europe Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 94. Europe Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 95. Germany Generic Injectables, by Type USD Million (2018-2023)
  • Table 96. Germany Generic Injectables, by Application USD Million (2018-2023)
  • Table 97. Germany Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 98. Germany Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 99. Germany Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 100. France Generic Injectables, by Type USD Million (2018-2023)
  • Table 101. France Generic Injectables, by Application USD Million (2018-2023)
  • Table 102. France Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 103. France Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 104. France Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 105. Italy Generic Injectables, by Type USD Million (2018-2023)
  • Table 106. Italy Generic Injectables, by Application USD Million (2018-2023)
  • Table 107. Italy Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 108. Italy Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 109. Italy Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 110. United Kingdom Generic Injectables, by Type USD Million (2018-2023)
  • Table 111. United Kingdom Generic Injectables, by Application USD Million (2018-2023)
  • Table 112. United Kingdom Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 113. United Kingdom Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 114. United Kingdom Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 115. Netherlands Generic Injectables, by Type USD Million (2018-2023)
  • Table 116. Netherlands Generic Injectables, by Application USD Million (2018-2023)
  • Table 117. Netherlands Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 118. Netherlands Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 119. Netherlands Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 120. Rest of Europe Generic Injectables, by Type USD Million (2018-2023)
  • Table 121. Rest of Europe Generic Injectables, by Application USD Million (2018-2023)
  • Table 122. Rest of Europe Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 123. Rest of Europe Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 124. Rest of Europe Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 125. MEA Generic Injectables, by Country USD Million (2018-2023)
  • Table 126. MEA Generic Injectables, by Type USD Million (2018-2023)
  • Table 127. MEA Generic Injectables, by Application USD Million (2018-2023)
  • Table 128. MEA Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 129. MEA Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 130. MEA Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 131. Middle East Generic Injectables, by Type USD Million (2018-2023)
  • Table 132. Middle East Generic Injectables, by Application USD Million (2018-2023)
  • Table 133. Middle East Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 134. Middle East Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 135. Middle East Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 136. Africa Generic Injectables, by Type USD Million (2018-2023)
  • Table 137. Africa Generic Injectables, by Application USD Million (2018-2023)
  • Table 138. Africa Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 139. Africa Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 140. Africa Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 141. North America Generic Injectables, by Country USD Million (2018-2023)
  • Table 142. North America Generic Injectables, by Type USD Million (2018-2023)
  • Table 143. North America Generic Injectables, by Application USD Million (2018-2023)
  • Table 144. North America Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 145. North America Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 146. North America Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 147. United States Generic Injectables, by Type USD Million (2018-2023)
  • Table 148. United States Generic Injectables, by Application USD Million (2018-2023)
  • Table 149. United States Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 150. United States Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 151. United States Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 152. Canada Generic Injectables, by Type USD Million (2018-2023)
  • Table 153. Canada Generic Injectables, by Application USD Million (2018-2023)
  • Table 154. Canada Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 155. Canada Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 156. Canada Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 157. Mexico Generic Injectables, by Type USD Million (2018-2023)
  • Table 158. Mexico Generic Injectables, by Application USD Million (2018-2023)
  • Table 159. Mexico Generic Injectables, by Route of Administration USD Million (2018-2023)
  • Table 160. Mexico Generic Injectables, by Distribution Channel USD Million (2018-2023)
  • Table 161. Mexico Generic Injectables, by Container Type USD Million (2018-2023)
  • Table 162. Generic Injectables Sales: by Type(M Units)
  • Table 163. Generic Injectables Sales Large Molecule Injectable {Monoclonal Antibodies (Mab), Insulin, And Others} , by Region M Units (2018-2023)
  • Table 164. Generic Injectables Sales Small Molecule Injectable , by Region M Units (2018-2023)
  • Table 165. Generic Injectables Sales: by Application(M Units)
  • Table 166. Generic Injectables Sales Oncology , by Region M Units (2018-2023)
  • Table 167. Generic Injectables Sales Infectious Diseases , by Region M Units (2018-2023)
  • Table 168. Generic Injectables Sales Cardiology , by Region M Units (2018-2023)
  • Table 169. Generic Injectables Sales Diabetes , by Region M Units (2018-2023)
  • Table 170. Generic Injectables Sales Immunology , by Region M Units (2018-2023)
  • Table 171. Generic Injectables Sales: by Route of Administration(M Units)
  • Table 172. Generic Injectables Sales Intravenous , by Region M Units (2018-2023)
  • Table 173. Generic Injectables Sales Intramuscular , by Region M Units (2018-2023)
  • Table 174. Generic Injectables Sales Subcutaneous , by Region M Units (2018-2023)
  • Table 175. Generic Injectables Sales Others , by Region M Units (2018-2023)
  • Table 176. Generic Injectables Sales: by Distribution Channel(M Units)
  • Table 177. Generic Injectables Sales Hospital Pharmacy , by Region M Units (2018-2023)
  • Table 178. Generic Injectables Sales Retail Pharmacy , by Region M Units (2018-2023)
  • Table 179. Generic Injectables Sales Drug Stores Online , by Region M Units (2018-2023)
  • Table 180. Generic Injectables Sales Prescription Stores , by Region M Units (2018-2023)
  • Table 181. Generic Injectables Sales Others , by Region M Units (2018-2023)
  • Table 182. Generic Injectables Sales: by Container Type(M Units)
  • Table 183. Generic Injectables Sales Vials , by Region M Units (2018-2023)
  • Table 184. Generic Injectables Sales Ampoules , by Region M Units (2018-2023)
  • Table 185. Generic Injectables Sales Premixes , by Region M Units (2018-2023)
  • Table 186. Generic Injectables Sales Prefilled Syringes , by Region M Units (2018-2023)
  • Table 187. Generic Injectables Sales Others , by Region M Units (2018-2023)
  • Table 188. South America Generic Injectables Sales, by Country M Units (2018-2023)
  • Table 189. South America Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 190. South America Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 191. South America Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 192. South America Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 193. South America Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 194. Brazil Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 195. Brazil Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 196. Brazil Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 197. Brazil Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 198. Brazil Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 199. Argentina Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 200. Argentina Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 201. Argentina Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 202. Argentina Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 203. Argentina Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 204. Rest of South America Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 205. Rest of South America Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 206. Rest of South America Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 207. Rest of South America Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 208. Rest of South America Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 209. Asia Pacific Generic Injectables Sales, by Country M Units (2018-2023)
  • Table 210. Asia Pacific Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 211. Asia Pacific Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 212. Asia Pacific Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 213. Asia Pacific Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 214. Asia Pacific Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 215. China Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 216. China Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 217. China Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 218. China Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 219. China Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 220. Japan Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 221. Japan Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 222. Japan Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 223. Japan Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 224. Japan Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 225. India Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 226. India Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 227. India Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 228. India Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 229. India Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 230. South Korea Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 231. South Korea Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 232. South Korea Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 233. South Korea Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 234. South Korea Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 235. Taiwan Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 236. Taiwan Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 237. Taiwan Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 238. Taiwan Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 239. Taiwan Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 240. Australia Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 241. Australia Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 242. Australia Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 243. Australia Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 244. Australia Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 245. Rest of Asia-Pacific Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 246. Rest of Asia-Pacific Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 247. Rest of Asia-Pacific Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 248. Rest of Asia-Pacific Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 249. Rest of Asia-Pacific Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 250. Europe Generic Injectables Sales, by Country M Units (2018-2023)
  • Table 251. Europe Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 252. Europe Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 253. Europe Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 254. Europe Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 255. Europe Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 256. Germany Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 257. Germany Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 258. Germany Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 259. Germany Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 260. Germany Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 261. France Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 262. France Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 263. France Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 264. France Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 265. France Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 266. Italy Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 267. Italy Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 268. Italy Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 269. Italy Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 270. Italy Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 271. United Kingdom Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 272. United Kingdom Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 273. United Kingdom Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 274. United Kingdom Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 275. United Kingdom Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 276. Netherlands Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 277. Netherlands Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 278. Netherlands Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 279. Netherlands Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 280. Netherlands Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 281. Rest of Europe Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 282. Rest of Europe Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 283. Rest of Europe Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 284. Rest of Europe Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 285. Rest of Europe Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 286. MEA Generic Injectables Sales, by Country M Units (2018-2023)
  • Table 287. MEA Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 288. MEA Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 289. MEA Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 290. MEA Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 291. MEA Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 292. Middle East Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 293. Middle East Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 294. Middle East Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 295. Middle East Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 296. Middle East Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 297. Africa Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 298. Africa Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 299. Africa Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 300. Africa Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 301. Africa Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 302. North America Generic Injectables Sales, by Country M Units (2018-2023)
  • Table 303. North America Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 304. North America Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 305. North America Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 306. North America Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 307. North America Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 308. United States Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 309. United States Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 310. United States Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 311. United States Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 312. United States Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 313. Canada Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 314. Canada Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 315. Canada Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 316. Canada Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 317. Canada Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 318. Mexico Generic Injectables Sales, by Type M Units (2018-2023)
  • Table 319. Mexico Generic Injectables Sales, by Application M Units (2018-2023)
  • Table 320. Mexico Generic Injectables Sales, by Route of Administration M Units (2018-2023)
  • Table 321. Mexico Generic Injectables Sales, by Distribution Channel M Units (2018-2023)
  • Table 322. Mexico Generic Injectables Sales, by Container Type M Units (2018-2023)
  • Table 323. Generic Injectables: by Type(USD/Units)
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Company Basic Information, Sales Area and Its Competitors
  • Table 328. Company Basic Information, Sales Area and Its Competitors
  • Table 329. Company Basic Information, Sales Area and Its Competitors
  • Table 330. Company Basic Information, Sales Area and Its Competitors
  • Table 331. Company Basic Information, Sales Area and Its Competitors
  • Table 332. Company Basic Information, Sales Area and Its Competitors
  • Table 333. Company Basic Information, Sales Area and Its Competitors
  • Table 334. Generic Injectables: by Type(USD Million)
  • Table 335. Generic Injectables Large Molecule Injectable {Monoclonal Antibodies (Mab), Insulin, And Others} , by Region USD Million (2025-2030)
  • Table 336. Generic Injectables Small Molecule Injectable , by Region USD Million (2025-2030)
  • Table 337. Generic Injectables: by Application(USD Million)
  • Table 338. Generic Injectables Oncology , by Region USD Million (2025-2030)
  • Table 339. Generic Injectables Infectious Diseases , by Region USD Million (2025-2030)
  • Table 340. Generic Injectables Cardiology , by Region USD Million (2025-2030)
  • Table 341. Generic Injectables Diabetes , by Region USD Million (2025-2030)
  • Table 342. Generic Injectables Immunology , by Region USD Million (2025-2030)
  • Table 343. Generic Injectables: by Route of Administration(USD Million)
  • Table 344. Generic Injectables Intravenous , by Region USD Million (2025-2030)
  • Table 345. Generic Injectables Intramuscular , by Region USD Million (2025-2030)
  • Table 346. Generic Injectables Subcutaneous , by Region USD Million (2025-2030)
  • Table 347. Generic Injectables Others , by Region USD Million (2025-2030)
  • Table 348. Generic Injectables: by Distribution Channel(USD Million)
  • Table 349. Generic Injectables Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 350. Generic Injectables Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 351. Generic Injectables Drug Stores Online , by Region USD Million (2025-2030)
  • Table 352. Generic Injectables Prescription Stores , by Region USD Million (2025-2030)
  • Table 353. Generic Injectables Others , by Region USD Million (2025-2030)
  • Table 354. Generic Injectables: by Container Type(USD Million)
  • Table 355. Generic Injectables Vials , by Region USD Million (2025-2030)
  • Table 356. Generic Injectables Ampoules , by Region USD Million (2025-2030)
  • Table 357. Generic Injectables Premixes , by Region USD Million (2025-2030)
  • Table 358. Generic Injectables Prefilled Syringes , by Region USD Million (2025-2030)
  • Table 359. Generic Injectables Others , by Region USD Million (2025-2030)
  • Table 360. South America Generic Injectables, by Country USD Million (2025-2030)
  • Table 361. South America Generic Injectables, by Type USD Million (2025-2030)
  • Table 362. South America Generic Injectables, by Application USD Million (2025-2030)
  • Table 363. South America Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 364. South America Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 365. South America Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 366. Brazil Generic Injectables, by Type USD Million (2025-2030)
  • Table 367. Brazil Generic Injectables, by Application USD Million (2025-2030)
  • Table 368. Brazil Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 369. Brazil Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 370. Brazil Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 371. Argentina Generic Injectables, by Type USD Million (2025-2030)
  • Table 372. Argentina Generic Injectables, by Application USD Million (2025-2030)
  • Table 373. Argentina Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 374. Argentina Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 375. Argentina Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 376. Rest of South America Generic Injectables, by Type USD Million (2025-2030)
  • Table 377. Rest of South America Generic Injectables, by Application USD Million (2025-2030)
  • Table 378. Rest of South America Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 379. Rest of South America Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 380. Rest of South America Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 381. Asia Pacific Generic Injectables, by Country USD Million (2025-2030)
  • Table 382. Asia Pacific Generic Injectables, by Type USD Million (2025-2030)
  • Table 383. Asia Pacific Generic Injectables, by Application USD Million (2025-2030)
  • Table 384. Asia Pacific Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 385. Asia Pacific Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 386. Asia Pacific Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 387. China Generic Injectables, by Type USD Million (2025-2030)
  • Table 388. China Generic Injectables, by Application USD Million (2025-2030)
  • Table 389. China Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 390. China Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 391. China Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 392. Japan Generic Injectables, by Type USD Million (2025-2030)
  • Table 393. Japan Generic Injectables, by Application USD Million (2025-2030)
  • Table 394. Japan Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 395. Japan Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 396. Japan Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 397. India Generic Injectables, by Type USD Million (2025-2030)
  • Table 398. India Generic Injectables, by Application USD Million (2025-2030)
  • Table 399. India Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 400. India Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 401. India Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 402. South Korea Generic Injectables, by Type USD Million (2025-2030)
  • Table 403. South Korea Generic Injectables, by Application USD Million (2025-2030)
  • Table 404. South Korea Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 405. South Korea Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 406. South Korea Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 407. Taiwan Generic Injectables, by Type USD Million (2025-2030)
  • Table 408. Taiwan Generic Injectables, by Application USD Million (2025-2030)
  • Table 409. Taiwan Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 410. Taiwan Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 411. Taiwan Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 412. Australia Generic Injectables, by Type USD Million (2025-2030)
  • Table 413. Australia Generic Injectables, by Application USD Million (2025-2030)
  • Table 414. Australia Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 415. Australia Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 416. Australia Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 417. Rest of Asia-Pacific Generic Injectables, by Type USD Million (2025-2030)
  • Table 418. Rest of Asia-Pacific Generic Injectables, by Application USD Million (2025-2030)
  • Table 419. Rest of Asia-Pacific Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 420. Rest of Asia-Pacific Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 421. Rest of Asia-Pacific Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 422. Europe Generic Injectables, by Country USD Million (2025-2030)
  • Table 423. Europe Generic Injectables, by Type USD Million (2025-2030)
  • Table 424. Europe Generic Injectables, by Application USD Million (2025-2030)
  • Table 425. Europe Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 426. Europe Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 427. Europe Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 428. Germany Generic Injectables, by Type USD Million (2025-2030)
  • Table 429. Germany Generic Injectables, by Application USD Million (2025-2030)
  • Table 430. Germany Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 431. Germany Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 432. Germany Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 433. France Generic Injectables, by Type USD Million (2025-2030)
  • Table 434. France Generic Injectables, by Application USD Million (2025-2030)
  • Table 435. France Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 436. France Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 437. France Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 438. Italy Generic Injectables, by Type USD Million (2025-2030)
  • Table 439. Italy Generic Injectables, by Application USD Million (2025-2030)
  • Table 440. Italy Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 441. Italy Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 442. Italy Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 443. United Kingdom Generic Injectables, by Type USD Million (2025-2030)
  • Table 444. United Kingdom Generic Injectables, by Application USD Million (2025-2030)
  • Table 445. United Kingdom Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 446. United Kingdom Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 447. United Kingdom Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 448. Netherlands Generic Injectables, by Type USD Million (2025-2030)
  • Table 449. Netherlands Generic Injectables, by Application USD Million (2025-2030)
  • Table 450. Netherlands Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 451. Netherlands Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 452. Netherlands Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 453. Rest of Europe Generic Injectables, by Type USD Million (2025-2030)
  • Table 454. Rest of Europe Generic Injectables, by Application USD Million (2025-2030)
  • Table 455. Rest of Europe Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 456. Rest of Europe Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 457. Rest of Europe Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 458. MEA Generic Injectables, by Country USD Million (2025-2030)
  • Table 459. MEA Generic Injectables, by Type USD Million (2025-2030)
  • Table 460. MEA Generic Injectables, by Application USD Million (2025-2030)
  • Table 461. MEA Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 462. MEA Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 463. MEA Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 464. Middle East Generic Injectables, by Type USD Million (2025-2030)
  • Table 465. Middle East Generic Injectables, by Application USD Million (2025-2030)
  • Table 466. Middle East Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 467. Middle East Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 468. Middle East Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 469. Africa Generic Injectables, by Type USD Million (2025-2030)
  • Table 470. Africa Generic Injectables, by Application USD Million (2025-2030)
  • Table 471. Africa Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 472. Africa Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 473. Africa Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 474. North America Generic Injectables, by Country USD Million (2025-2030)
  • Table 475. North America Generic Injectables, by Type USD Million (2025-2030)
  • Table 476. North America Generic Injectables, by Application USD Million (2025-2030)
  • Table 477. North America Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 478. North America Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 479. North America Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 480. United States Generic Injectables, by Type USD Million (2025-2030)
  • Table 481. United States Generic Injectables, by Application USD Million (2025-2030)
  • Table 482. United States Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 483. United States Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 484. United States Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 485. Canada Generic Injectables, by Type USD Million (2025-2030)
  • Table 486. Canada Generic Injectables, by Application USD Million (2025-2030)
  • Table 487. Canada Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 488. Canada Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 489. Canada Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 490. Mexico Generic Injectables, by Type USD Million (2025-2030)
  • Table 491. Mexico Generic Injectables, by Application USD Million (2025-2030)
  • Table 492. Mexico Generic Injectables, by Route of Administration USD Million (2025-2030)
  • Table 493. Mexico Generic Injectables, by Distribution Channel USD Million (2025-2030)
  • Table 494. Mexico Generic Injectables, by Container Type USD Million (2025-2030)
  • Table 495. Generic Injectables Sales: by Type(M Units)
  • Table 496. Generic Injectables Sales Large Molecule Injectable {Monoclonal Antibodies (Mab), Insulin, And Others} , by Region M Units (2025-2030)
  • Table 497. Generic Injectables Sales Small Molecule Injectable , by Region M Units (2025-2030)
  • Table 498. Generic Injectables Sales: by Application(M Units)
  • Table 499. Generic Injectables Sales Oncology , by Region M Units (2025-2030)
  • Table 500. Generic Injectables Sales Infectious Diseases , by Region M Units (2025-2030)
  • Table 501. Generic Injectables Sales Cardiology , by Region M Units (2025-2030)
  • Table 502. Generic Injectables Sales Diabetes , by Region M Units (2025-2030)
  • Table 503. Generic Injectables Sales Immunology , by Region M Units (2025-2030)
  • Table 504. Generic Injectables Sales: by Route of Administration(M Units)
  • Table 505. Generic Injectables Sales Intravenous , by Region M Units (2025-2030)
  • Table 506. Generic Injectables Sales Intramuscular , by Region M Units (2025-2030)
  • Table 507. Generic Injectables Sales Subcutaneous , by Region M Units (2025-2030)
  • Table 508. Generic Injectables Sales Others , by Region M Units (2025-2030)
  • Table 509. Generic Injectables Sales: by Distribution Channel(M Units)
  • Table 510. Generic Injectables Sales Hospital Pharmacy , by Region M Units (2025-2030)
  • Table 511. Generic Injectables Sales Retail Pharmacy , by Region M Units (2025-2030)
  • Table 512. Generic Injectables Sales Drug Stores Online , by Region M Units (2025-2030)
  • Table 513. Generic Injectables Sales Prescription Stores , by Region M Units (2025-2030)
  • Table 514. Generic Injectables Sales Others , by Region M Units (2025-2030)
  • Table 515. Generic Injectables Sales: by Container Type(M Units)
  • Table 516. Generic Injectables Sales Vials , by Region M Units (2025-2030)
  • Table 517. Generic Injectables Sales Ampoules , by Region M Units (2025-2030)
  • Table 518. Generic Injectables Sales Premixes , by Region M Units (2025-2030)
  • Table 519. Generic Injectables Sales Prefilled Syringes , by Region M Units (2025-2030)
  • Table 520. Generic Injectables Sales Others , by Region M Units (2025-2030)
  • Table 521. South America Generic Injectables Sales, by Country M Units (2025-2030)
  • Table 522. South America Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 523. South America Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 524. South America Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 525. South America Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 526. South America Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 527. Brazil Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 528. Brazil Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 529. Brazil Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 530. Brazil Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 531. Brazil Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 532. Argentina Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 533. Argentina Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 534. Argentina Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 535. Argentina Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 536. Argentina Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 537. Rest of South America Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 538. Rest of South America Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 539. Rest of South America Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 540. Rest of South America Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 541. Rest of South America Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 542. Asia Pacific Generic Injectables Sales, by Country M Units (2025-2030)
  • Table 543. Asia Pacific Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 544. Asia Pacific Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 545. Asia Pacific Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 546. Asia Pacific Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 547. Asia Pacific Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 548. China Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 549. China Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 550. China Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 551. China Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 552. China Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 553. Japan Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 554. Japan Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 555. Japan Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 556. Japan Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 557. Japan Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 558. India Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 559. India Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 560. India Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 561. India Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 562. India Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 563. South Korea Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 564. South Korea Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 565. South Korea Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 566. South Korea Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 567. South Korea Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 568. Taiwan Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 569. Taiwan Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 570. Taiwan Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 571. Taiwan Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 572. Taiwan Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 573. Australia Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 574. Australia Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 575. Australia Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 576. Australia Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 577. Australia Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 578. Rest of Asia-Pacific Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 579. Rest of Asia-Pacific Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 580. Rest of Asia-Pacific Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 581. Rest of Asia-Pacific Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 582. Rest of Asia-Pacific Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 583. Europe Generic Injectables Sales, by Country M Units (2025-2030)
  • Table 584. Europe Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 585. Europe Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 586. Europe Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 587. Europe Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 588. Europe Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 589. Germany Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 590. Germany Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 591. Germany Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 592. Germany Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 593. Germany Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 594. France Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 595. France Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 596. France Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 597. France Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 598. France Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 599. Italy Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 600. Italy Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 601. Italy Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 602. Italy Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 603. Italy Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 604. United Kingdom Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 605. United Kingdom Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 606. United Kingdom Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 607. United Kingdom Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 608. United Kingdom Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 609. Netherlands Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 610. Netherlands Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 611. Netherlands Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 612. Netherlands Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 613. Netherlands Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 614. Rest of Europe Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 615. Rest of Europe Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 616. Rest of Europe Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 617. Rest of Europe Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 618. Rest of Europe Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 619. MEA Generic Injectables Sales, by Country M Units (2025-2030)
  • Table 620. MEA Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 621. MEA Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 622. MEA Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 623. MEA Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 624. MEA Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 625. Middle East Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 626. Middle East Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 627. Middle East Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 628. Middle East Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 629. Middle East Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 630. Africa Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 631. Africa Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 632. Africa Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 633. Africa Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 634. Africa Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 635. North America Generic Injectables Sales, by Country M Units (2025-2030)
  • Table 636. North America Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 637. North America Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 638. North America Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 639. North America Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 640. North America Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 641. United States Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 642. United States Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 643. United States Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 644. United States Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 645. United States Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 646. Canada Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 647. Canada Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 648. Canada Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 649. Canada Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 650. Canada Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 651. Mexico Generic Injectables Sales, by Type M Units (2025-2030)
  • Table 652. Mexico Generic Injectables Sales, by Application M Units (2025-2030)
  • Table 653. Mexico Generic Injectables Sales, by Route of Administration M Units (2025-2030)
  • Table 654. Mexico Generic Injectables Sales, by Distribution Channel M Units (2025-2030)
  • Table 655. Mexico Generic Injectables Sales, by Container Type M Units (2025-2030)
  • Table 656. Generic Injectables: by Type(USD/Units)
  • Table 657. Research Programs/Design for This Report
  • Table 658. Key Data Information from Secondary Sources
  • Table 659. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Generic Injectables: by Type USD Million (2018-2023)
  • Figure 5. Global Generic Injectables: by Application USD Million (2018-2023)
  • Figure 6. Global Generic Injectables: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Generic Injectables: by Distribution Channel USD Million (2018-2023)
  • Figure 8. Global Generic Injectables: by Container Type USD Million (2018-2023)
  • Figure 9. South America Generic Injectables Share (%), by Country
  • Figure 10. Asia Pacific Generic Injectables Share (%), by Country
  • Figure 11. Europe Generic Injectables Share (%), by Country
  • Figure 12. MEA Generic Injectables Share (%), by Country
  • Figure 13. North America Generic Injectables Share (%), by Country
  • Figure 14. Global Generic Injectables: by Type M Units (2018-2023)
  • Figure 15. Global Generic Injectables: by Application M Units (2018-2023)
  • Figure 16. Global Generic Injectables: by Route of Administration M Units (2018-2023)
  • Figure 17. Global Generic Injectables: by Distribution Channel M Units (2018-2023)
  • Figure 18. Global Generic Injectables: by Container Type M Units (2018-2023)
  • Figure 19. South America Generic Injectables Share (%), by Country
  • Figure 20. Asia Pacific Generic Injectables Share (%), by Country
  • Figure 21. Europe Generic Injectables Share (%), by Country
  • Figure 22. MEA Generic Injectables Share (%), by Country
  • Figure 23. North America Generic Injectables Share (%), by Country
  • Figure 24. Global Generic Injectables: by Type USD/Units (2018-2023)
  • Figure 25. Global Generic Injectables share by Players 2023 (%)
  • Figure 26. Global Generic Injectables share by Players (Top 3) 2023(%)
  • Figure 27. Global Generic Injectables share by Players (Top 5) 2023(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Sandoz International (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Sandoz International (Germany) Revenue: by Geography 2023
  • Figure 33. Sagent Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 34. Sagent Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 35. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Baxter International Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Fresenius Medical Care AG & Co. KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 38. Fresenius Medical Care AG & Co. KGaA (Germany) Revenue: by Geography 2023
  • Figure 39. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Mylan N.V. (United States) Revenue: by Geography 2023
  • Figure 41. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 42. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 43. Hikma Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 44. Hikma Pharmaceuticals (United Kingdom) Revenue: by Geography 2023
  • Figure 45. Lupin Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 46. Lupin Pharmaceuticals (India) Revenue: by Geography 2023
  • Figure 47. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 48. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 49. Global Generic Injectables: by Type USD Million (2025-2030)
  • Figure 50. Global Generic Injectables: by Application USD Million (2025-2030)
  • Figure 51. Global Generic Injectables: by Route of Administration USD Million (2025-2030)
  • Figure 52. Global Generic Injectables: by Distribution Channel USD Million (2025-2030)
  • Figure 53. Global Generic Injectables: by Container Type USD Million (2025-2030)
  • Figure 54. South America Generic Injectables Share (%), by Country
  • Figure 55. Asia Pacific Generic Injectables Share (%), by Country
  • Figure 56. Europe Generic Injectables Share (%), by Country
  • Figure 57. MEA Generic Injectables Share (%), by Country
  • Figure 58. North America Generic Injectables Share (%), by Country
  • Figure 59. Global Generic Injectables: by Type M Units (2025-2030)
  • Figure 60. Global Generic Injectables: by Application M Units (2025-2030)
  • Figure 61. Global Generic Injectables: by Route of Administration M Units (2025-2030)
  • Figure 62. Global Generic Injectables: by Distribution Channel M Units (2025-2030)
  • Figure 63. Global Generic Injectables: by Container Type M Units (2025-2030)
  • Figure 64. South America Generic Injectables Share (%), by Country
  • Figure 65. Asia Pacific Generic Injectables Share (%), by Country
  • Figure 66. Europe Generic Injectables Share (%), by Country
  • Figure 67. MEA Generic Injectables Share (%), by Country
  • Figure 68. North America Generic Injectables Share (%), by Country
  • Figure 69. Global Generic Injectables: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Sandoz International (Germany)
  • Sagent Pharmaceuticals (United States)
  • Baxter International Inc. (United States)
  • Fresenius Medical Care AG & Co. KGaA (Germany)
  • Mylan N.V. (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Hikma Pharmaceuticals (United Kingdom)
  • Lupin Pharmaceuticals (India)
  • Sanofi S.A. (France)
Additional players considered in the study are as follows:
Biocon Limited (India)
Select User Access Type

Key Highlights of Report


Feb 2024 245 Pages 54 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Generic Injectables Quantitative research analysis
Global Generic Injectables Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer Inc. (United States), Sandoz International (Germany), Sagent Pharmaceuticals (United States), Baxter International Inc. (United States), Fresenius Medical Care AG & Co. KGaA (Germany), Mylan N.V. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Hikma Pharmaceuticals (United Kingdom), Lupin Pharmaceuticals (India) and Sanofi S.A. (France) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technology Advancement regrading Generic Injectable" is seen as one of major influencing trends for Generic Injectables Market during projected period 2023-2030.
The Generic Injectables market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Generic Injectables Report?

Have a Query? Click Here

Other Related Reports

Chemotherapy Infusion Pumps Comprehensive Study by Type (LVP (Large Volume Pump), Syringe Pump, Elastomeric Pumps), Application (Hospital & Clinic, Home Care), Distribution Channel (Online Channel, O...
$ 3500
Newborn Screening Instruments Comprehensive Study by Type (Pulse Oximeter, Mass Spectrometer, Hearing Screening Devices, Laparoscopes, Retinoscopes, Ultrasound Machines, Others), Application (Dry Blo...
$ 3750
Temporary Pacemaker Comprehensive Study by Type (Single Chamber, Dual-Chamber, Triple Chamber), Application (Hospital, Medical Research Organization, Mobile Clinics), End User type (Arrhythmia and Ca...
$ 3650
Pain Management Devices Comprehensive Study by Type (Electrical Stimulators, Radiofrequency Ablation, Analgesic Infusion Pumps, Neurostimulation), Application (Neuropathic Pain, Cancer Pain, Facial P...
$ 3650
Transradial Access Comprehensive Study by Type (Catheters, Guidewires, Sheaths & Sheath Introducers, Accessories), Application (Drug Administration, Fluid & Nutrition Administration, Blood Transfusio...
$ 3650
Hemodialysis Catheter Comprehensive Study by Type (Cuffed Tunneled Catheter, Non-cuffed Tunneled Catheter), Application (Home Dialysis, In-center Dialysis), End-users (Hospitals, Clinics, Others), Di...
$ 3650